Study of seroprevalence of antibodies to SARS-COV-2 among the healthy blood donors of Jammu region

• Published in: International journal of research in medical sciences Vol. 10; no. 2; p. 495
• Main Authors: Dutt, Neeti, Sharma, Sushil, Sidhu, Meena
• Format: Journal Article
• Language: English
• Published: 29.01.2022
• ISSN: 2320-6071; 2320-6012
• DOI: 10.18203/2320-6012.ijrms20220298

Background: SARS‑CoV‑2 emerged in China and spread throughout the world due to its rapid transmission. The exposure rate in the healthy population is unknown, mainly in resource‑limited countries. Herein, we estimated the seroprevalence of anti‑SARS‑CoV‑2 antibodies and risk factors among blood donors at our blood bank and to describe some characteristics of those that test positive. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV2 during the peak period of the COVID-19 pandemic in Jammu State, India to know the magnitude of SARS-CoV-2 exposure, the prevalence of herd immunity in the population.Methods: This is prospective observational study of COVID-19 seroprevalence among blood donors that complied with blood donation protocol. Participation in study was voluntary after taking proper consent on the consent form.Results: A total of 750 random blood donors who voluntarily participated, were enrolled in this study after obtaining their proper consent on the consent form. Out of 750 donors, 287 (38.2%) were positive for IgG antibodies and 463 (61.7%) were negative for IgG antibodies. In our study, male donors (745) outnumbered the female donors but on the other hand female donors showed a higher prevalence of covid antibodies i.e., 60% as compared to male donors i.e., 38% which is a statistically significant difference (p<0.005).Conclusions: A high prevalence of SARS-CoV-2 antibodies was detected among blood donors which indicated a high level of exposure to the virus within the population and development of innate immunity against the virus. This could help us to introduce a protocol of antibody testing in the screening of blood donors to enhance the number of plasma donation cases for the treatment of serious COVID patients.